Gene therapy has the potential to treat and ultimately cure many diseases, including cancer and cardiovascular disease. It relies on the transfer of genetic material such as DNA to the site of disease. Clinical trials have demonstrated the feasibility of this approach, but also documented shortcomings in the efficiency of DNA delivery. Several technologies have the ability to carry DNA to cells and are being investigated in the laboratory or the clinic. The most recent addition to this list is ultrasound, having the ability to cause the internalization of genetic material into cells, where it can function in a therapeutic way. This review addresses the issues pertinent to gene therapy from the perspective of gene delivery and highlights the usefulness of ultrasound in this field.
Background
Gene therapy is the modification of the gene expression of cells for therapeutic purposes. This is done by delivering genetic material to cells. Several methods are being used for this delivery and ultrasound is one such method.
Most cells contain DNA in their nuclei, and it is replicated and passed along generations. Every individual's cells contain the exact same DNA sequences inherited from their parents. DNA holds the code for the production of proteins, which mediate every cellular function. This code is transcribed into RNA, which leaves the nucleus and translocates to the cytoplasm of the cell where it becomes translated to protein. This DNA-to-RNA-to-protein chain is called the central dogma of biology.
Errors (mutations) in the genetic code may lead to the production of a flawed protein, potentially unable to perform its task fully. A mutation in a structural protein such as dystrophin (involved in muscle function) is often inherited and leads to various forms of muscular dystrophy. Similarly, inherited mutations lead to inherited diseases such as cystic fibrosis, haemophilias, anaemias, auto-immune and metabolic diseases. A mutation in proteins that control cell growth may cause uncontrolled proliferation and, thereby, possibly tumours. It is accepted that oncogenesis is caused by an accumulation of mutations.
Concept
Classical gene therapy aims to correct the disease cased by a mutation by transferring a correct copy of the mutated gene to diseased cells. The new copy should produce the healthy protein and restore normal function to the cell. In theory, if the transferred gene, also called the transgene, can persist in the nucleus of the target cell for life, then the genetic correction will also be life-long. This is currently not feasible, as most gene therapy systems can only achieve transient delivery and, therefore, correction.
As an alternative to the delivery of an entire gene, several strategies have been developed. A so called 'mini-gene', composed of only selected portions of the whole gene, may confer a function relatively similar to that of the whole gene, but is often substantially easier to deliver. Oligonucleotides of under 100 nucleotides (the building blocks of DNA), have also been used for a variety of reasons. They may divert the transcription mechanism that reads the gene (decoy), or the cellular systems that edit the message read from the gene (RNA) before it exits the nucleus to be translated (e.g. exon skipping). Alternatively, oligonucleotides may be used to bind to RNA in the cytoplasm and restrict its translation (antisense). More novel strategies have used specific double-stranded RNA sequences that lead to the destruction of normal cellular RNA containing the same sequence. They utilize a more recently identified antiviral mechanism used by cells against double-stranded RNA viruses, the retroviruses. They are called short interfering RNAs (siRNA) and the strategy is called RNA interference (RNAi). Most of these strategies, such as antisense, decoy and RNAi, aim to limit or block the expression of a gene that causes disease. 1, 2 The exon-skipping approach is used in the case of muscular dystrophy with promising results in order to produce a functional protein by editing the RNA. 3 Because of their relatively small size, oligonucleotides are easier to deliver to areas of interest, but only lead to transient correction.
Technology
Regardless of the nature of the nucleic acid being delivered, gene therapy is reliant on a technology capable of performing this transfer in a wide variety of cells. There is a need for efficient gene vectors. 4 The further advancement of gene therapy has, however, been consistently bedevilled by shortcomings of the vector technology. 5 An applicable vector will have to be able to deliver DNA to the desired cells or tissues efficiently, safely and with no or acceptable side effects. A number of vector systems have been developed and used, with varying levels of success. 6 They can broadly be divided in two categories, viral and non-viral. 7 As their name implies, viral vectors derive from viruses, 8, 9 and have usually undergone large-scale manipulation in order to be made safe and nontoxic, as well as to improve their efficiency in vivo. 8 Non-viral vectors as a group are a diverse array of synthetic compounds that have the ability to bind DNA and protect it through the different stages required for entry into the nucleus of target cells 10 or a variety of methods that mechanically deliver the DNA to the target cells. 11 The commonest viral vectors are based on the retrovirus, the adenovirus and the adeno-associated virus (AAV). Being among the first vectors used, the retroviruses have played a pivotal role in the development of vector-making technologies. 8, 9 They are small viruses with an RNA genome that have the ability to integrate their genome and any transgene carried, in the host cell genome, 12 so they can potentially maintain long-term expression of the therapeutic gene. One limitation of the common retroviruses is that they can only infect dividing cells, as break down of the nuclear envelope is essential for nuclear entry. 13 Nuclear entry, however, is necessary for expression of the transgene. Human Immunodeficiency Virus (HIV)-based vectors, however, another member of the retroviruses (part of the lentivirus sub-class), are able to overcome this limitation. Due to public concerns though, they have so far remained largely preclinical. Another concern associated with all retroviruses is insertion of the retroviral genome in or close to a functional gene, disrupting the normal function of that gene. That was seen in a French anti-severe combined immunodeficiency (SCID) trial in children, where the viral genome integrated very near a leukaemia-associated gene resulting in a leukaemialike condition in the patients. [14] [15] [16] [17] Adenoviral vectors are the second most popular vector type. Currently, 172 clinical trials have been registered, five of which are now in phase III. The main reasons for this are the easy to grow virus to high titres as well as the ability of recombinant adenoviral vectors to achieve high levels of transgene expression. 18 A very important limitation with the use of adenovirus-derived gene vectors is the significant immune reaction against the virus. 5, 19 This inflammatory nature of the virus was underlined by the death of a patient participate of a clinical trial for the treatment of ornithine transcarbamylase (OTC) deficiency in 1999. 20 In addition, the immune reaction produced will reduce the effect of additional administrations of the gene therapy. Current research is primarily aimed at overcoming this limitation.
The adeno-associated virus (AAV) is a small, nonpathogenic, single-stranded DNA parvovirus, with a genome of 4 . 7 kb. 21 As the name implies, however, the AAV requires co-infection with adenovirus 22 or Herpes Simplex Virus 23 as a helper virus in order to replicate. Another important feature of the AAV is its ability to integrate in a specific position in the small arm of chromosome 19. 24 AAV exhibits a wide tropism for infection and can infect both dividing and non-dividing cells, although some cells are resistant to infection, but this can be overcome by using different AAV serotypes. 25 Due to their lack of pathogenicity, as well as their ability to transfect post-mitotic cells and integrate adeno-associated viruses, predominantly AAV1, were used as a platform for the development of gene delivery vectors. 26 The non-viral delivery vectors encompass a wide variety of systems that have the ability to transfer of DNA or RNA into cells, 10 obviously excluding viral vectors. As a consequence, this is a very diverse category. They can be divided into two categories: physical and chemical. The chemical methods utilize the ability of a growing list of compounds that can bind DNA, condense and protect it, facilitate entry into cells and subsequently cellular nuclei. Cationic compounds bind DNA by virtue of electrical change, protect it and mediate internalization. They are either cationic lipids (liposomes), synthetic polymers, or combinations of the above. Cationic lipids have been used since the 80s. 27 They have since been constantly optimized, improved and used in clinical trials with variable results. Cationic polymer-based vectors are a diverse category of macromolecules that include polyethyleneimine (PEI), polylysine, chitosan, poly-L-ornithine and starburst dendrimers. They all bind DNA due to their positive charge, forming what is sometimes called a polyplex and have been shown to afford DNA different levels of condensation and protection against cellular and/or restriction nucleases, and mediate transfection efficiency. 28 Physical methods involve either a simple direct injection of naked DNA (usually local), bombardment of cells with gold or tungsten micro-particles coated with DNA using a 'gene gun', electroporation, or ultrasound.
Direct injection of naked DNA, usually plasmid DNA, is the simplest form of gene deliver. 29 It has been shown by a number of reports that intramuscular or intradermal injection of plasmid DNA can lead to expression of that DNA, although the efficiency is low and is restricted to the site of injection, but new methods are being employed in order to increase its efficiency. 30 It is mostly being investigated as a method of vaccination.
Electroporation is a common method that improves the efficiency of naked plasmid DNA. 11 It involves the application of an electrical current onto cells to permeabilize the cell membrane that can thus take up macromolecules such as DNA or RNA. In principle, electroporation is a method used to increase the transfection efficiency of naked DNA injection. After injection, electric pulses are delivered by means of two electrodes placed on either side of the injection site. 31 It is now known that this enhancement in gene delivery is due to both increased permeability of the target cell membranes, as well as electrophoresis of the DNA. 32 Obviously, without surgical procedures, this method is limited to skin and muscle. It may be difficult to envisage use of this method to human patients, even though it has become a fairly popular laboratory method of gene transfer. Figure 1 shows the intracellular pathway followed by the different vector technologies. The viral and chemical (lipid and polymer) vectors use the endocytic pathway. Following attachment onto the cell surface, the vector becomes internalized in an endosomal vesicle in a process that demands energy. Maturation of the endosome in a lysosome will destroy the contents, so the vector/DNA complex will need to escape by endosomal disruption for successful transfection to occur. The DNA will then need to be transported to the nucleus where it can be transcribed. Electroporation and ultrasound-mediated gene delivery are able to by-pass the endosomal pathway. They deliver DNA into the cell by increasing the permeability of the cellular membrane. The only subsequent step required is therefore nuclear localization.
Ultrasound-mediated Gene Delivery
Ultrasound-mediated gene delivery is the newest strategy being investigated for the delivery of nucleic acids to cells. The primary bioeffects that ultrasound can have on tissues is heating and cavitation. The latter is thought to be responsible for ultrasound-mediated gene delivery. 33 Cavitation induced by bubbles, also known as cavitation nuclei, form on gas-aqueous interfaces in an ultrasound field and increase local bioeffects. Acoustic cavitation leads to reversible, sub-lethal, membrane damage that in 1987 was first shown to permit the exchange of macromolecules between the cell and its surroundings, and the entrapment of macromolecules inside the cell. 34 Fechheimer et al., used low frequency ultrasound (20 kHz) to obtain these highly promising results, delivering a plasmid commonly used in anti-cancer studies, that has the ability to activate the cytotoxic drug gancyclovir in cells. Medical US, however, usually uses higher frequencies in the MHz range and so the initial experiments of Fechheimer cannot be repeated with the ultrasound equipment available in the clinic. US-mediated gene delivery using 1 MHz was optimized much later, by investigating parameters such as temperature, pressure amplitude, on-off timing (duty cycle), and exposure duration. 35 Several similar studies have been performed, confirming and further optimizing the effects of US in the transfection of several cell lines and cells in vitro. 33 This effect is sometimes referred to as sonoporation. Some studies have attempted to understand the mechanism. By measuring the loss of haemoglobin, it was shown that very high levels of membrane permeabilization can be achieved in erythrocytes. 36 It was shown by another group that there may be three cell sub-populations that are distinguishable by their ability to show 'high', 'nominal' and 'low' uptake after exposure to ultrasound. 37 Figure 2 shows a common experimental setup for transfection of cells with ultrasound. A water tank is used as water is a good mediator of ultrasound. For in vivo use, a gel is applied over the area to be insonated. The signal is produced by an ultrasound machine and delivered by a probe.
Uptake can be further enhanced by microbubbles which increase the bioeffects of ultrasound by forming 'artificial cavitation nuclei'. 38 Microbubbles, as their name implies are between 1-10 mm wide and are made up of a protein (often albumin), lipid, or polymer shell. They are filled with either air or inert gasses such as perfluorocarbon. 39 Several such agents are in clinical use today. Promising results with microbubbles with regards to drug or gene delivery are now being frequently reported in the literature, and this is a dynamic and rapidly developing field. 40, 41 Microbubble-enhanced gene delivery was optimized in human muscle cells in vitro, 42 and then transferred in vivo to a mouse model by us 43 and others, 44 showing significant increase in transfection efficiency. This was further enhanced by the use of Optison, a common microbubble agent that has been shown to be amongst the best in its class for gene delivery. 45 Figure 3 shows muscle fibres transfected with a gene than encodes for green fluorescent protein (GFP) with no ultrasound (a,b), with ultrasound (c,d) and with ultrasound and Optison (e,f). a, c and e show the positive fibres (green) while b, d and f show the damage caused by the treatment. This is reduced by the use of Optison and ultrasound (f). The muscle is an important target system not only for the treatment of muscular dystrophies, but also because any protein produced in the muscle can be secreted in the circulation where it may play a therapeutic role. 46 Optison was also used to transfect human saphenous vein ex vivo with a marker gene. 47 These results were repeated with a second-generation lipid-based microbubble and were followed by the delivery of a therapeutic gene, TIMP-3 (tissue inhibitor of metalloproteinases-3). 48 The veins transfected with the TIMP-3 gene were grafted in a pig model and showed significant reduction in intimal thickening, a common cause of graft failure of such saphenous vein grafts in human patients following cardiac by-pass surgery. Another study transferred a marker gene 49 or an oligonucleotide decoy designed to inhibit the expression of the E2F transcription factor, an important element in cellular proliferation. 50 The authors used a balloon catheter to induce injury to the carotid artery of rats in order to emulate some of the symptoms seen in atherosclerotic plaques. They then clamped the artery, injected the decoy with Optison and insonated the site. Rats treated with the decoy showed significant reduction of intimal hyperplasia compared to control animals. Optison was also used to transfect mouse kidney in vivo with high efficiency. 51 Again, the authors clamped the renal artery and vein before ultrasound application and achieved transfection of 70-80% of glomeruli. Optison was also used to enable gene transfer to rat central nervous system 52 in vivo. The same microbubble agent was used to deliver reporter genes to fetal mice by intrauterine injection. 53 Despite the many promising reports of the use of microbubble ultrasound-mediated gene delivery, the exact mechanism involved is ill understood. Mathematical modelling suggested, supported by some experimental data, that the increased uptake seen with microbubble contrast agents is a result of microbubble expansion, collapse and subsequent shock waves. 54 Cell survival after ultrasound treatment has been shown to be dependent on peak negative pressure and exposure time and in extreme cases may reach 0%. 37 This would obviously be a problem in many clinical applications where we want to avoid major damage to target tissues. Uptake is thought to involve the formation of pores on the membrane of cells or other alterations to membrane morphology. The only limited evidence for this by electron microscopy, showing images of pores in cell membranes after prolonged ultrasound has been applied. 55 In addition to pore formation however, 'ruffling' of the cellular membranes was observed by the same group in a different report, 56 and that may point to the existence of mechanisms alternative or complementary to the large pores seen. Other ways of permeabilization could be increased, such short lived perforations, mechanical pressure, flip-flops between lipids of the outer and inner plasma membrane, thinning of the membrane or even the activation of active transport mechanisms due to cellular stress. Imaging techniques such as electron microscopy would not be able to detect such small changes in cell membranes. We recently used fluorescently labelled molecules to quantify the uptake at different time-points following ultrasound in cells in vitro. We showed that uptake can only be achieved when the fluorescent marker is present during the insonation process and ceases within a second of removal of ultrasound. The use of Optison enhances the levels of uptake, but also prolongs the actual uptake for almost a second after removal of ultrasound.
Ultrasound-mediated gene delivery has several advantages over some other methods. Unlike electroporation, a method also used to enhance the delivery of naked DNA, it can also be applied to deep tissues. Delivery can be targeted to areas of interest simply by placing the ultrasound probe over the appropriate target organ. Traditional non-viral vectors such as polymers and liposomes utilize cellular uptake mechanisms in order to enter the cell. Endocytosis is the most common such mechanism that internalizes compounds in specialize d compartments. The vector-DNA complexes need to escape from these endosomes, otherwise they will be destroyed by acidification of the compartment. This step proves especially treacherous and is often a significant limitation of transfection efficiency. 57 Ultrasound is thought to avoid this pathway and instead transport the DNA directly to the cytoplasm through perforations of the cell membrane. We have shown that in doing so, ultrasound can yield transgene expression levels similar to those of a commonly used commercial polymer (Superfect) from much lower levels of uptake (work in progress). This means that much less destruction of the DNA has occurred and therefore a much larger proportion of what has been delivered is in fact expressed. What is more, ultrasound-mediated gene delivery can sidestep the immunogenicity observed with viral vectors. The plasmid or oligonucleotide may still become cleared by cells of the immune system carrying receptors that recognize DNA. 58 Although the advantages of ultrasound as a gene delivery method are clear, it is also obvious that several limitations still exist. When compared to viral or even some non-viral vectors the gene transfer efficiency is still poor. As it is necessary for the ultrasound, microbubbles and DNA to concurrently exist over the site of delivery, several investigators have resorted to clamping the vein or artery before delivery and insonation, or local delivery. These are issues that current and future work will need to resolve.
The Future
The majority of microbubbles that have been used for gene delivery were designed for imaging applications, rather than gene delivery per se. As mentioned above, our experience in these microbubbles is largely evidence-based. It is not known why one microbubble is better than another. 59 Physical characterization and comparison of the different agents in use will no doubt provide some valuable clues for the production of second-generation microbubbles, designed specifically for the purposes of gene delivery. It may prove useful to target the microbubbles by using antibodies. This has been performed using antibodies against inflammatory or angiogenic markers. 39 Antibody-targeted gene delivery is a field of growing popularity among gene therapists and the method is being trialled with a variety of gene delivery vectors. 60 Microbubbles have been targeted against a hepatocellular carcinoma-specific antigen, 61 or against a molecule expressed during vascular inflammation (intracellular adhesion molecule-1 -ICAM-1) in order to image acute cardiac transplant rejection in rats. 62 Targeted gene delivery by using antibody-labelled microbubbles may therefore be a viable possibility. 63 This may avoid the need for clamping of the local circulation. Another concern is the fate of the DNA if it is applied intravenously in circulation. It may be cleared by specialized immune cells or simply degraded. There is also no guarantee that the DNA and the microbubbles will co-exist over the target area during the ultrasound application. Attachment of the DNA to microbubbles by manufacturing of microbubbles with a cationic lipid shell may overcome these concerns. Cationic lipid microbubbles were used in one study to enhance gene delivery to muscle in vivo by 200-fold, after intravenous injection in mice. 64 Several other advances either in microbubble production and ultrasound instrumentation are constantly taking place with imaging and diagnosis in mind. 65 These advances will also provide the field of ultrasoundmediated gene delivery with ammunition for further development. Better understanding of the basic biology behind the uptake mechanism involved will greatly help this newly developing field become a clinical reality.
